Maze Therapeutics, Inc. Common Stock (MAZE) - Net Assets
Based on the latest financial reports, Maze Therapeutics, Inc. Common Stock (MAZE) has net assets worth $379.44 Million USD as of September 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($422.06 Million) and total liabilities ($42.62 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Maze Therapeutics, Inc. Common Stock liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $379.44 Million |
| % of Total Assets | 89.9% |
| Annual Growth Rate | 39.29% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 974.28 |
Maze Therapeutics, Inc. Common Stock - Net Assets Trend (2022–2024)
This chart illustrates how Maze Therapeutics, Inc. Common Stock's net assets have evolved over time, based on quarterly financial data. Also explore Maze Therapeutics, Inc. Common Stock assets under control for the complete picture of this company's asset base.
Annual Net Assets for Maze Therapeutics, Inc. Common Stock (2022–2024)
The table below shows the annual net assets of Maze Therapeutics, Inc. Common Stock from 2022 to 2024. For live valuation and market cap data, see market cap of Maze Therapeutics, Inc. Common Stock.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | $196.90 Million | +1858.46% |
| 2023-12-31 | $10.05 Million | -90.09% |
| 2022-12-31 | $101.44 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Maze Therapeutics, Inc. Common Stock's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 6315600000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $2.00K | 0.00% |
| Other Components | $555.33 Million | 282.03% |
| Total Equity | $196.90 Million | 100.00% |
Maze Therapeutics, Inc. Common Stock Competitors by Market Cap
The table below lists competitors of Maze Therapeutics, Inc. Common Stock ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Yantai Changyu Pioneer Wine Co Ltd
SHE:000869
|
$1.30 Billion |
|
East China Engineering Science and Technology Co Ltd
SHE:002140
|
$1.30 Billion |
|
Shenzhen Terca Technology Co Ltd
SHE:002213
|
$1.30 Billion |
|
Labrador Iron Ore Royalty Corp
TO:LIF
|
$1.30 Billion |
|
Siam City Cement Public Company Limited
BK:SCCC
|
$1.30 Billion |
|
Yihai International Holding Ltd
F:YIR
|
$1.30 Billion |
|
Shanxi Blue Flame Holding Co Ltd
SHE:000968
|
$1.30 Billion |
|
S&S TECH Corporation
KQ:101490
|
$1.30 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Maze Therapeutics, Inc. Common Stock's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 10,054,000 to 196,904,000, a change of 186,850,000 (1858.5%).
- Net income of 52,231,000 contributed positively to equity growth.
- New share issuances of 70,793,000 increased equity.
- Other factors increased equity by 63,826,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $52.23 Million | +26.53% |
| Share Issuances | $70.79 Million | +35.95% |
| Other Changes | $63.83 Million | +32.41% |
| Total Change | $- | 1858.46% |
Book Value vs Market Value Analysis
This analysis compares Maze Therapeutics, Inc. Common Stock's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 5.99x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 11.62x to 5.99x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $2.32 | $26.93 | x |
| 2023-12-31 | $0.23 | $26.93 | x |
| 2024-12-31 | $4.50 | $26.93 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Maze Therapeutics, Inc. Common Stock utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 26.53%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 31.18%
- • Asset Turnover: 0.70x
- • Equity Multiplier: 1.22x
- Recent ROE (26.53%) is above the historical average (-361.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -113.31% | 0.00% | 0.00x | 1.48x | $-125.08 Million |
| 2023 | -998.76% | 0.00% | 0.00x | 7.11x | $-101.42 Million |
| 2024 | 26.53% | 31.18% | 0.70x | 1.22x | $32.54 Million |
Industry Comparison
This section compares Maze Therapeutics, Inc. Common Stock's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $180,435,080
- Average return on equity (ROE) among peers: -26.88%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Maze Therapeutics, Inc. Common Stock (MAZE) | $379.44 Million | -113.31% | 0.11x | $1.30 Billion |
| Aardvark Therapeutics, Inc. Common Stock (AARD) | $-27.92 Million | 0.00% | 0.00x | $114.75 Million |
| Abcellera Biologics Inc (ABCL) | $1.14 Billion | -12.83% | 0.19x | $1.07 Billion |
| Abeona Therapeutics Inc (ABEO) | $-17.08 Million | 0.00% | 0.00x | $292.09 Million |
| Acumen Pharmaceuticals Inc (ABOS) | $188.78 Million | -22.70% | 0.04x | $179.09 Million |
| Abpro Holdings, Inc. (ABP) | $-22.46 Million | 0.00% | 0.00x | $2.00 Million |
| Absci Corp (ABSI) | $274.41 Million | -38.23% | 0.17x | $345.85 Million |
| Arbutus Biopharma Corp (ABUS) | $106.02 Million | -68.71% | 0.36x | $840.56 Million |
| ABVC Biopharma Inc (ABVC) | $13.30 Million | -59.47% | 0.58x | $26.92 Million |
| Abivax SA American Depositary Shares (ABVX) | $34.02 Million | -17.32% | 0.13x | $9.29 Billion |
| ACADIA Pharmaceuticals Inc (ACAD) | $113.93 Million | -49.49% | 0.18x | $3.78 Billion |
About Maze Therapeutics, Inc. Common Stock
Maze Therapeutics, Inc., a clinical stage biopharmaceutical company, develops small molecule precision medicines for the treatment of renal, cardiovascular, related metabolic diseases, and obesity in the United States. Its lead programs include MZE829, an oral small molecule inhibitor of apolipoprotein L1, or APOL1, which is in phase II clinical trial for the treatment of patients with APOL1 kidn… Read more